EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study

Wilma Barcellini iD, Fabrizio Pane, Andrea Patriarca, Irina Murakhovskaya, Louis Terriou, Maria T DeSancho iD, Wahid T Hanna, Lance Leopold, Erica Rappold, Ke Szeto, Shaoceng Wei, Ulrich Jäger iD

American Journal of Hematology · 2024-12 · 99 (12) · 2313-2320

DOI: 10.1002/ajh.27493 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 22.10.2024. Verfasst von Wilma Barcellini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune hemolytic anemia (AIHA) is a group of acquired autoimmune disorders characterized by red blood cell hemolysis. In a phase 2, open‐label, multicenter study, adults with warm AIHA, cold agglutinin disease, or mixed‐type AIHA were administered once‐daily 1.0 or 2.5 mg parsaclisib (selective phosphoinositide 3‐kinase δ inhibitor) orally for 12 weeks, followed by an extension period. Dose increases (for AIHA worsening) or decreases (for tolerability) were permitted. Primary efficacy endpoint was the proportion of patients with complete (≥12 g/dL hemoglobin [Hgb]) or partial (10–12 g/dL Hgb or ≥2 g/dL increase from baseline) response at any visit during weeks 6–12 not attributable to transfusion. Among 25 enrolled patients (median age, 63 y), 16 (64%) achieved a partial or complete Hgb response during weeks 6–12. Responses were observed by week 1 in 52.0% of patients with incremental improvements during weeks 6–12 and sustained responses during the extension period. Responses were higher among patients with warm AIHA versus other types (75.0% vs. 44.4%). Clinically meaningful improvements in Functional Assessment of Chronic Illness Therapy‐Fatigue scores were observed at weeks 6 and 12. All patients had treatment‐emergent adverse events (TEAEs), most commonly diarrhea (32.0%) and pyrexia (28.0%). Grade ≥3 TEAEs occurred in 13 patients (52.0%). TEAEs considered possibly related to treatment occurred in 11 patients (44.0%). No dose reductions were required; six patients (24%) discontinued for a TEAE. In summary, parsaclisib was well tolerated and resulted in substantial improvements in Hgb response at week 1, with durable responses through the extension period. Clinical trial registration This trial was registered at ClinicalTrials.gov (NCT03538041).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, AutoimmuneHumansMiddle AgedFemaleMaleAgedAdultHemoglobinsPhosphoinositide-3 Kinase InhibitorsTreatment OutcomeAged, 80 and over

Substanzen

HemoglobinsPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Medicine and Surgery, University Federico II of Naples, Naples, Italy.
  • University of Eastern Piedmont and AOU "Maggiore della Carità", Novara, Italy.
  • Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA.
  • Université de Lille, Inserm, CHU Lille, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), INFINITE-Institute for Translational Research in Inflammation, Lille, Fra…
  • Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York, USA.

ORCID-Profile: Wilma Barcellini, Maria T DeSancho, Ulrich Jäger

Förderung

  • Incyte

Zitieren

APA

Barcellini, W., Pane, F., Patriarca, A., Murakhovskaya, I., Terriou, L., DeSancho, M. T., Hanna, W. T., Leopold, L., Rappold, E., Szeto, K., Wei, S., & Jäger, U. (2024). Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study. American Journal of Hematology, 99(12), 2313-2320. https://doi.org/10.1002/ajh.27493

Vancouver

Barcellini W, Pane F, Patriarca A, Murakhovskaya I, Terriou L, DeSancho MT, et al. Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study. American Journal of Hematology. 2024;99(12):2313-2320. doi:10.1002/ajh.27493

BibTeX
@article{Barcellini2024,
  author = {Barcellini, Wilma and Pane, Fabrizio and Patriarca, Andrea and Murakhovskaya, Irina and Terriou, Louis and DeSancho, Maria T and Hanna, Wahid T and Leopold, Lance and Rappold, Erica and Szeto, Ke and Wei, Shaoceng and Jäger, Ulrich},
  title = {Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {12},
  pages = {2313--2320},
  doi = {10.1002/ajh.27493}
}
Kostenlos starten →